NextGen Healthcare Fully Prevails in Hussein Trial Jury Verdict

Article Stock Quotes (1)

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 8/24/2026

1. WMT
2. JMKE
3. ROST
4. NVDA
5. AAP

6. SPY
7. BABA
8. REF
9. TSLA
10. AVGO

Get Alerts NXGN Hot Sheet

Price: $23.94 --0%

Overall Analyst Rating:
SELL (= Flat)

Join SI Premium – FREE

Trial Completed; NextGen Healthcare Confirms No Liability and No Change to Q1FY22 Financial Results

ATLANTA--(BUSINESS WIRE)-- NextGen Healthcare, Inc. (Nasdaq: NXGN), a leading provider of ambulatory-focused technology solutions, announced that the Ahmed D. Hussein v. Sheldon Razin, Steven Plochocki and Quality Systems, Inc. lawsuit filed in the Superior Court of the State of California for the County of Orange on October 7, 2013 concluded on July 29, 2021 with a jury verdict in favor of the Company and Messrs. Razin and Plochocki on all counts with no financial liability for the Company. As such, no adjustments are necessary to the Company’s Q1FY22 financials, which were reported on July 29, 2021, just over an hour before the jury returned its verdict. The Company will file its Quarterly Report on Form 10-Q today on Friday, July 30, 2021.

Safe Harbor Provision

Please refer to the Q1F22 earnings release dated July 29, 2021 for Safe Harbor Provisions and Forward-Looking Statement.

About NextGen Healthcare, Inc.

NextGen Healthcare, Inc. (Nasdaq: NXGN) is a leading provider of ambulatory-focused technology solutions. We are empowering the transformation of ambulatory care—partnering with medical, behavioral, and dental providers in their journey to value-based care to make healthcare better for everyone. We go beyond EHR and PM. Our integrated solutions help increase clinical productivity, enrich the patient experience, and ensure healthy financial outcomes. We believe in better. Learn more at nextgen.com, and follow us on Facebook, Twitter, LinkedIn, YouTube and Instagram.